GLUE Latest Headlines

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Monte Rosa Therapeutics (GLUE) and Curis (CRIS)

at www.tipranks.com (Sun, 22-Mar 8:30 AM)

J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

at www.tipranks.com (Thu, 19-Mar 7:59 AM)

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE)

at www.tipranks.com (Wed, 18-Mar 7:50 AM)

Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

at www.tipranks.com (Wed, 18-Mar 6:45 AM)

Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX)

at www.tipranks.com (Tue, 17-Mar 5:20 PM)

Monte Rosa Therapeutics reports Q4 results

at seekingalpha.com (Tue, 17-Mar 7:25 AM)

GLUE’s Upcoming Phase 2 Prostate Cancer Trial Highlights Promise of MRT-2359 and Apalutamide Combination

Market Chameleon (Mon, 16-Mar 8:40 AM)

Monte Rosa Therapeutics Secures $300 Million Through Underwritten Public Offering—What Does This Mean for GLUE?

Market Chameleon (Fri, 9-Jan 8:57 AM)

GLUE’s $200 Million Public Offering Proposal Spotlights Bold Expansion Strategy

Market Chameleon (Thu, 8-Jan 11:55 AM)

GLUE Jumps as Monte Rosa Readies Interim MRT-8102 Data: What Should Investors Watch Ahead of the Conference Call?

Market Chameleon (Wed, 7-Jan 9:54 AM)

GLUE’s MRT-8102 Shows 85% Reduction in Inflammatory Marker—Data Points to Broad Impact in CVD

Market Chameleon (Wed, 7-Jan 7:05 AM)